HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer.

AbstractPURPOSE:
S-1 chemotherapy is effective against advanced biliary tract cancer. The purpose was to evaluate the efficacy and safety of S-1-based concurrent chemoradiotherapy in patients with advanced biliary tract cancer.
METHODS:
Patients with pathologically-proven advanced biliary tract cancer were eligible. S-1 was orally administered at a dose of 40 mg/m(2), twice daily from day 1 to 14 and from day 22 to 35; concurrent radiotherapy of 180-200 cGy per fraction was delivered in 25-28 fractions. After treatment completion, tumor response was evaluated by computed tomography. In the first stage of the optimal two-stage phase II design, 18 patients were required.
RESULTS:
Twenty patients were enrolled between August 2006 and February 2009. The median age was 62.5 years (range 45-77 years). The median follow-up time was 11.6 months (range 1.9-49.1 months). Fifteen patients (75%) had extrahepatic cholangiocarcinoma, two patients (10%) had intrahepatic cholangiocarcinoma, and three patients (15%) had gallbladder cancer. After treatment, a partial response was achieved in three patients (15%), and stable disease was achieved in 14 patients (70%). The overall response rate was 15%, and the disease stabilization rate was 85%. There was no grade 4 toxicity or treatment-related death. The common grade 3 toxicities were thrombocytopenia (15%), neutropenia (10%), and nausea (10%). The median progression-free survival and median overall survival were 5.9 months (range 2.2-9.5 months) and 10.8 months (range 1.1-20.4 months), respectively.
CONCLUSIONS:
This study shows that S-1-based concurrent chemoradiotherapy is feasible and tolerable in patients with advanced biliary tract cancer. It will be further confirmed in a following large-scale phase II study.
AuthorsHee Man Kim, Kyong Joo Lee, Jihye Cha, Moon Jae Chung, Seungmin Bang, Jinsil Seong, Si Young Song, Seung Woo Park
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 74 Issue 4 Pg. 861-5 (Oct 2014) ISSN: 1432-0843 [Electronic] Germany
PMID25129491 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
Topics
  • Antineoplastic Agents (administration & dosage, adverse effects)
  • Biliary Tract Neoplasms (drug therapy, pathology)
  • Chemoradiotherapy (methods)
  • Disease-Free Survival
  • Drug Combinations
  • Drug Screening Assays, Antitumor
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Oxonic Acid (administration & dosage, adverse effects)
  • Pilot Projects
  • Tegafur (administration & dosage, adverse effects)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: